Goldman Sachs Downgrades Cepheid to 'Neutral' | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Goldman Sachs on Tuesday downgraded Cepheid shares to "Neutral" from "Buy," citing the stock's outperformance compared to its peer group and a less attractive risk/reward at current levels.

In a research note, Issac Ro noted strong performance by Cepheid's stock and expected continued growth at the company, but expressed concern over its high price-to-sales multiple of 7.4 times, compared to a median of 2.6 times for its peer group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.